• 1
    Locasciulli A,Testa M,Pontisso P, et al. Hepatitis C virus genotypes and liver disease in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant 1997; 19: 237240.
  • 2
    Besson C,Canioni D,Lepage E, et al. Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs. J Clin Oncol 2006; 24: 953960.
  • 3
    Kanamori H,Fukawa H,Maruta A, et al. Case report: Fulminant hepatitis C viral infection after allogeneic bone marrow transplantation. Am J Med Sci 1992; 303: 109111.
  • 4
    Zuckerman E,Zuckerman T,Douer D, et al. Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies. Cancer 1998; 83: 12241230.
  • 5
    Luppi M,Longo G,Ferrari MG, et al. Additional neoplasms and HCV infection in low-grade lymphoma of MALT type. Br J Haematol 1996; 94: 373375.
  • 6
    Kawatani T,Suou T,Tajima F, et al. Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies. Eur J Haematol 2001; 67: 4550.
  • 7
    Coiffier B. Hepatitis B virus reactivation in patients receiving chemotherapy for cancer treatment: Role of Lamivudine prophylaxis. Cancer Invest 2006; 24: 548552.
  • 8
    Dai MS,Lu JJ,Chen YC, et al. Reactivation of precore mutant hepatitis B virus in chemotherapy-treated patients. Cancer 2001; 92: 29272932.
  • 9
    Hamaki T,Kami M,Kusumi E, et al. Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximab. Am J Hematol 2001; 68: 292294.
  • 10
    Dai MS,Chao TY,Kao WY, et al. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol 2004; 83: 769774.
  • 11
    Tsutsumi Y,Kanamori H,Mori A, et al. Reactivation of hepatitis B virus with rituximab. Expert Opin Drug Saf 2005; 4: 599608.
  • 12
    Coiffier B,Haioun C,Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 1998; 92: 19271932.
  • 13
    Vose JM,Link BK,Grossbard ML, et al. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 2001; 19: 389397.
  • 14
    Sarrecchia C,Cappelli A,Aiello P. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J Infect Chemother 2005; 11: 189191.
  • 15
    Tsutsumi Y,Kanamori H,Minami H, et al. Successful treatment of lymphoma with fludarabine combined with rituximab after immune thrombocytopenia induced by fludarabine. Ann Hematol 2005; 84: 269271.
  • 16
    Okamoto H,Kobata S,Tokita H, et al. A second-generation method of genotyping hepatitis C virus by the polymerase chain reaction with sense and antisense primers deduced from the core gene. J Virol Methods 1996; 57: 3145.
  • 17
    Okamoto H,Tokita H,Sakamoto M, et al. Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection. J Gen Virol 1993; 74: 23852390.
  • 18
    JaffeE. S. HNL, SteinH, VardimanJW, editors. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissue. 2001.
  • 19
    Bedossa P,Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289293.
  • 20
    Nieters A,Kallinowski B,Brennan P, et al. Hepatitis C and risk of lymphoma: Results of the European multicenter case–control study EPILYMPH. Gastroenterology 2006; 131: 18791886.
  • 21
    Locasciulli A,Bruno B,Alessandrino EP, et al. Hepatitis reactivation and liver failure in haemopoietic stem cell transplants for hepatitis B virus (HBV)/hepatitis C virus (HCV) positive recipients: A retrospective study by the Italian group for blood and marrow transplantation. Bone Marrow Transplant 2003; 31: 295300.
  • 22
    Maruta A,Kanamori H,Fukawa H, et al. Liver function tests of recipients with hepatitis C virus infection after bone marrow transplantation. Bone Marrow Transplant 1994; 13: 417422.
  • 23
    Fong TL,Valinluck B,Govindarajan S, et al. Short-term prednisone therapy affects aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C. Gastroenterology 1994; 107: 196199.
  • 24
    Vento S,Cainelli F,Mirandola F, et al. Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus. Lancet 1996; 347: 9293.
  • 25
    Visco C,Arcaini L,Brusamolino E, et al. Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: Analysis of 156 patients from northern Italy. Ann Oncol 2006; 17: 14341440.
  • 26
    Aksoy S,Abali H,Kilickap S, et al. Accelerated hepatitis C virus replication with rituximab treatment in a non-Hodgkin's lymphoma patient. Clin Lab Haematol 2006; 28: 211214.
  • 27
    Rumi MG,De Filippi F,La Vecchia C, et al. Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: A retrospective cohort study of 206 untreated patients. Gut 2005; 54: 402406.
  • 28
    Coppola N,Vatiero LM,Sagnelli E. HCV genotype 2 as a risk factor for reactivation of chronic HCV infection. Gut 2005; 54: 1207.
  • 29
    Carman WF,Jacyna MR,Hadziyannis S, et al. Mutation preventing formation of hepatitis B antigen in patients with chronic hepatitis B infection. Lancet 1989; 2: 588591.
  • 30
    Okamoto H,Yotsumoto S,Akahane Y, et al. Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen. J Virol 1990; 64: 12981303.